Century Therapeutics Stock Performance
| IPSC Stock | USD 0.56 0.01 1.82% |
The firm shows a Beta (market volatility) of 1.61, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Century Therapeutics will likely underperform. At this point, Century Therapeutics has a negative expected return of -0.91%. Please make sure to confirm Century Therapeutics' value at risk and the relationship between the accumulation distribution and relative strength index , to decide if Century Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Century Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Pluristyx Announces Immediate Availability of GMP-Compliant PSXi013 iPSC Line for Advanced Therapy Development | 01/07/2025 |
2 | Century Therapeutics Receives Buy Rating from HC Wainwright | 01/22/2025 |
3 | Disposition of 351 shares by Carr Douglas of Century Therapeutics at 0.78 subject to Rule 16b-3 | 02/03/2025 |
4 | Century Therapeutics COO Farid Adrienne sells 822 in stock - Investing.com | 02/05/2025 |
5 | Disposition of 63616 shares by Luis Borges of Century Therapeutics at 1.03 subject to Rule 16b-3 | 02/13/2025 |
6 | Disposition of 34712 shares by Pfeiffenberger Brent of Century Therapeutics at 0.783 subject to Rule 16b-3 | 02/18/2025 |
7 | Century Therapeutics CEO Makes Significant Stock Sale - TipRanks | 02/20/2025 |
8 | Acquisition by Adrienne Farid of 485 shares of Century Therapeutics at 1.03 subject to Rule 16b-3 | 02/25/2025 |
9 | uBriGene Biosciences Submits Drug Master File for iPSC Reprogramming mRNA-LNP Kit | 03/04/2025 |
10 | Disposition of 1240 shares by Carr Douglas of Century Therapeutics at 0.615 subject to Rule 16b-3 | 03/10/2025 |
11 | Disposition of 2359 shares by Adrienne Farid of Century Therapeutics at 0.615 subject to Rule 16b-3 | 03/12/2025 |
12 | Century Therapeutics GAAP EPS of -1.61 misses by 0.23, revenue of 6.59M beats by 3.24M | 03/19/2025 |
13 | Century Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags | 03/21/2025 |
| Begin Period Cash Flow | 49.3 M |
Century |
Century Therapeutics Relative Risk vs. Return Landscape
If you would invest 102.00 in Century Therapeutics on December 23, 2024 and sell it today you would lose (46.00) from holding Century Therapeutics or give up 45.1% of portfolio value over 90 days. Century Therapeutics is currently does not generate positive expected returns and assumes 3.6221% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Century, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Century Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Century Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Century Therapeutics, and traders can use it to determine the average amount a Century Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2521
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IPSC |
Estimated Market Risk
| 3.62 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.91 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Century Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Century Therapeutics by adding Century Therapeutics to a well-diversified portfolio.
Century Therapeutics Fundamentals Growth
Century Stock prices reflect investors' perceptions of the future prospects and financial health of Century Therapeutics, and Century Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Century Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (8.22) % | ||||
| Current Valuation | (88.27 M) | ||||
| Shares Outstanding | 86.05 M | ||||
| Price To Earning | 86.08 X | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 7.25 X | ||||
| Revenue | 6.59 M | ||||
| Gross Profit | (100.66 M) | ||||
| EBITDA | (111.47 M) | ||||
| Net Income | (126.57 M) | ||||
| Cash And Equivalents | 378.76 M | ||||
| Cash Per Share | 6.43 X | ||||
| Total Debt | 48.96 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.79 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (110.14 M) | ||||
| Earnings Per Share | (1.61) X | ||||
| Market Capitalization | 47.75 M | ||||
| Total Asset | 353.22 M | ||||
| Retained Earnings | (782.34 M) | ||||
| Working Capital | 64.27 M | ||||
About Century Therapeutics Performance
By analyzing Century Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Century Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Century Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Century Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (22.90) | (21.76) | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.78) | (0.75) |
Things to note about Century Therapeutics performance evaluation
Checking the ongoing alerts about Century Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Century Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Century Therapeutics generated a negative expected return over the last 90 days | |
| Century Therapeutics has some characteristics of a very speculative penny stock | |
| Century Therapeutics has high historical volatility and very poor performance | |
| Century Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.59 M. Net Loss for the year was (126.57 M) with loss before overhead, payroll, taxes, and interest of (100.66 M). | |
| Century Therapeutics currently holds about 378.76 M in cash with (110.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Century Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags |
- Analyzing Century Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Century Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Century Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Century Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Century Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Century Therapeutics' stock. These opinions can provide insight into Century Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |